NDAOPHTHALMICEMULSION
Approved
Jun 2021
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
6/8 — Strong
VERKAZIA (cyclosporine) by Novartis is calcineurin inhibitors [moa]. Approved for dry eye disease, kidney transplantation, liver transplantation and 2 more indications. First approved in 2021.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VERKAZIA is a cyclosporine ophthalmic emulsion approved by the FDA in June 2021 for dry eye disease and other ocular inflammatory conditions. It is a calcineurin inhibitor that acts as a partial immunomodulator to suppress ocular inflammation and increase tear production. The drug addresses a significant unmet need in the ophthalmology market where existing therapies have limited efficacy.
$0.283MPart D
Peak3.1 years to LOEEarly peak-phase product with modest Part D spend signals a niche ophthalmology franchise requiring specialized medical and commercial teams to drive adoption in a high-competition market.
Mechanism of Action
Calcineurin Inhibitors
Pharmacologic Class:
Calcineurin Inhibitor Immunosuppressant
Indications (5)
Worked on VERKAZIA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.